Analyst Price Targets — TBPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:36 am | — | H.C. Wainwright | $17.00 | $17.00 | TheFly | Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright |
| March 4, 2026 7:11 am | Mayank Mamtani | B.Riley Financial | $14.00 | $13.96 | StreetInsider | B.Riley Downgrades Theravance Biopharma (TBPH) to Neutral |
| December 3, 2025 11:16 am | — | Oppenheimer | $27.00 | $18.43 | TheFly | Theravance Biopharma initiated with an Outperform at Oppenheimer |
| November 26, 2025 12:14 pm | — | BTIG | $40.00 | $18.94 | TheFly | Theravance Biopharma price target raised to $40 from $25 at BTIG |
| November 13, 2024 2:39 pm | David Risinger | Leerink Partners | $10.00 | $7.66 | StreetInsider | Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH) |
| August 6, 2024 6:08 am | Douglas Tsao | H.C. Wainwright | $15.00 | $9.59 | TheFly | Theravance Biopharma price target lowered to $15 from $20 at H.C. Wainwright |
| April 12, 2024 6:36 am | Julian Harrison | BTIG | $21.00 | $8.93 | StreetInsider | BTIG Starts Theravance Biopharma (TBPH) at Buy |
| November 17, 2022 6:03 am | — | Leerink Partners | $14.00 | $11.22 | Benzinga | SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14 |
Latest News for TBPH
Empowered Funds LLC acquired a new position in Theravance Biopharma, Inc. (NASDAQ: TBPH) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 55,463 shares of the biopharmaceutical company's stock, valued at approximately $900,000. Empowered Funds LLC owned 0.11% of Theravance
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share.Hal
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.…
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Previously announced acquisition by Zymeworks expected to close in second half of 2026 YUPELRI ® Collaboration Revenue increased 11% year-over-year 1, from $18.7 million to $20.7 million, driven by continued Net Sales growth and improved operating leverage Organizational restructuring and cost reduction initiatives delivered 35% reduction in operating expenses year-over-year (excluding restructuring and transaction…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TBPH.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.